During the corresponding time, Teleflex Incorporated saw a revenue deteriorated by -26.89 % year on year, sequentially revenue grew by 4.18 %. While revenue at the Teleflex Incorporated's corporate clients
Teleflex Incorporated's Comment on Sales, Marketing and Customers
The company focuses exclusively on the medical device industry following the divestiture of its aerospace, automotive, industrial, and marine businesses. It sold certain respiratory product lines to Medline Industries, Inc. The company has announced strategic divestitures of its Acute Care and Interventional Urology businesses to Intersurgical® Ltd and its OEM business to Montagu and Kohlberg, with completion expected in the second half of 2026. The company operates through three reportable segments: Americas, EMEA (Europe, the Middle East, and Africa), and Asia (Asia Pacific), providing medical technology products to hospitals and healthcare providers.
In the rapidly evolving medical technology landscape, Teleflex Incorporated has marked a significant milestone by showcasing its latest innovations aimed at enhancing patient care. Recently presented data at the ASTRO 2024 conference shed light on the safety and efficacy of the Barrigel Rectal Spacer, a pioneering solution transforming radiation therapy for prostate cancer patients. Concurrently, Teleflex has unveiled two additional strategic initiatives, namely the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) and the expansion of its intraosseous vascular access portfolio with the launch of the Arrow EZ-IO Intraosseous Access Procedure Tray. Together, these innovations reaffirm T...
Teleflex Announces New Initiatives to Revolutionize Medical TechnologiesWAYNE, Pa., (Date) - Teleflex Incorporated, a global leader in medical technologies, has recently unveiled several groundbreaking advancements in the healthcare industry. The company announced the establishment of the Teleflex Center for Antimicrobial Protection (TCAP) as a strategic branch of its Vascular Access business unit. In addition, Teleflex has also introduced the limited market release of the Wattson Temporary Pacing Guidewire and the upcoming full market release of the UroLift 2 System with Advanced Tissue Control. These innovative developments mark significant advancements in their respective fields and demonstrate Teleflex s...
In a recent announcement, global medical technology company, Teleflex, has unveiled its groundbreaking innovation the Wattson Temporary Pacing Guidewire. This remarkable advancement is set to expand the company s structural heart portfolio, positioning Teleflex as a leading player in the field of interventional cardiology.The limited market release of the bipolar temporary pacing guidewire is a significant development for Teleflex. This cutting-edge technology aims to facilitate the introduction and precise placement of catheters and other interventional devices within the heart chambers. Additionally, it enables the transmission of an electrical signal from an external pulse generator to the heart, making i...
Teleflex Incorporated, a preeminent worldwide supplier of medical technologies, has announced the full market launch of the highly anticipated UroLift 2 System with Advanced Tissue Control (ATC). Building on the legacy of the original UroLift system, this revolutionary development promises to revolutionize treatment for men suffering symptoms of benign prostatic hyperplasia (BPH) across all prostate sizes - up to 100g.The UroLift 2 System s novel ATC feature has recently received clearance from the U.S. Food and Drug Administration (FDA), thereby paving the way for its full-scale market release. The highly sophisticated system is expected to offer enhanced, personalized care to BPH patients across a spectrum...
-In a recent announcement, global provider of medical technologies Teleflex has pledged to achieve net-zero greenhouse gas emissions across its entire value chain by 2050. This firm commitment positions Teleflex at the forefront of the fight against climate change within the healthcare sector, signalling a substantial shift in the industry s approach to sustainable business practices. This pledge was endorsed by the Science Based Targets initiative (SBTi), lending it a substantial degree of credibility and ensuring that Teleflex s targets align with the latest climate science. SBTi is a partnership established by leading non-profit organizations, striving to promote ambitious corporate climate action by empl...
Teleflex Incorporated’s Comment on Sales, Marketing and Customers
The company focuses exclusively on the medical device industry following the divestiture of its aerospace, automotive, industrial, and marine businesses. It sold certain respiratory product lines to Medline Industries, Inc. The company has announced strategic divestitures of its Acute Care and Interventional Urology businesses to Intersurgical® Ltd and its OEM business to Montagu and Kohlberg, with completion expected in the second half of 2026. The company operates through three reportable segments: Americas, EMEA (Europe, the Middle East, and Africa), and Asia (Asia Pacific), providing medical technology products to hospitals and healthcare providers.
Sources:
Teleflex Incorporated’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Teleflex Incorporated’s corporate clients.
For your research, we’ve provided 9 tables on Teleflex Incorporated corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
84.71 %